Medtronic (MDT) Tops Q4 EPS by 4c; guides below

Medtronic (NYSE: MDT) reported Q4 EPS of $1.62, $0.04 better than the analyst estimate of $1.58. Revenue for the quarter came in at $8.93 billion versus the consensus estimate of $8.82 billion.

GUIDANCE:

Medtronic sees FY2026 EPS of $5.50-$5.60, versus the consensus of $5.83. The company is guiding to FY26 organic revenue growth of approximately 5%.

For earnings history and earnings-related data on Medtronic (MDT) click here.

You May Also Be Interested In

• Barrick Mining said to delay IPO of American gold business to 2027
• Medtronic, Inc. (MDT) PT Raised to $104 at Wells Fargo
• Medtronic, Inc. (MDT) PT Raised to $95 at Stifel on Beat-and-Raise Quarter